Edwin E. Jeng
AbbVie (United States)(US)
Publications by Year
Research Areas
Lung Cancer Research Studies, HER2/EGFR in Cancer Research, CRISPR and Genetic Engineering, Molecular Biology Techniques and Applications, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions(2017)530 cited
- → Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation(2018)408 cited
- → Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens(2017)396 cited
- → The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D(2021)156 cited
- → Systematic Identification of Host Cell Regulators of Legionella pneumophila Pathogenesis Using a Genome-wide CRISPR Screen(2019)94 cited
- → Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities(2020)45 cited
- → A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer(2024)27 cited
- → First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.(2023)18 cited
- → CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia(2018)15 cited
- → Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5(2023)15 cited